×
About 2,755 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  1,093 results

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993095
Blood Advances; Lim KH, Wu JN et. al.

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

Vascular endothelial growth factors and angiopoietins as new players in mastocytosis.
https://doi.org/10.1007/s10238-021-00693-0 10.3390/ijms20122976 10.1182/blood.2019000932 10.1182/asheducation-2018.1.127 10.1007/s12016-017-8619-2 10.1016/j.iac.2016.08.017 10.1158/0008-5472.CAN-16-2234 10.1016/j.jaci.2017.06.007 10.1159/000500088 10.3389/fncel.2019.00299 10.3390/ijms20102380 10.3390/ijms20143400 10.1016/j.it.2020.06.006 10.3390/ijms20174241 10.3390/ijms20122851 10.1016/j.coph.2014.07.002 10.3390/ijms20184397 10.1136/annrheumdis-2018-213418 10.3390/ijms20081828 10.3390/ijms20092106 10.3390/ijms20184413 10.1111/imr.12634 10.3389/fimmu.2014.00569 10.3389/fimmu.2018.02601 10.1159/000353316 10.1016/j.jaci.2009.01.044 10.1016/j.ejphar.2015.03.088 10.1084/jem.188.6.1135 10.4049/jimmunol.172.2.1227 10.1091/mbc.9.4.875 10.1073/pnas.1000803107 10.1172/JCI70212 10.1038/nrc.2017.51 10.1172/JCI71603 10.3390/vaccines8020208 10.1126/science.6823562 10.1200/JCO.2002.10.088 10.1016/j.cell.2017.10.009 10.1016/S0092-8674(00)81812-7 10.1016/j.cytogfr.2013.05.009 10.1073/pnas.1018925108 10.1152/ajpheart.00621.2002 10.1172/JCI99659 10.1371/journal.pone.0192395 10.1182/blood-2011-08-375816 10.1016/j.intimp.2019.106079 10.1111/all.12862 10.1097/01.shk.0000150728.91155.41 10.1097/MD.0000000000000878 10.1016/j.cyto.2015.01.022 10.1182/blood-2016-09-731893 10.1073/pnas.92.23.10560 10.1182/blood-2013-10-534685 10.1067/mai.2002.120524 10.1124/jpet.105.086553 10.1126/science.277.5322.55 10.1038/nrd.2016.278 10.1182/blood-2009-02-205237 10.1159/000501079 10.1111/j.1398-9995.2010.02372.x 10.18632/oncotarget.4213 10.1016/j.it.2006.10.004 10.3390/cells8050471 10.1016/S0092-8674(00)81813-9 10.1158/0008-5472.CAN-10-4635 10.1096/fj.11-182287 10.1042/CS20160129 10.1038/nature09513 10.1182/blood-2008-12-195941 10.1172/JCI46322 10.1038/74725 10.1182/blood-2003-10-3685 10.1038/nm1351 10.1371/journal.pone.0089148 10.1007/s11882-009-0010-9 10.1203/00006450-200212000-00016 10.1038/nri3690 10.1016/j.jaci.2004.02.032 10.1172/JCI118337 10.1056/NEJM198706253162603 10.1111/j.1365-2362.2009.02184.x 10.1189/jlb.3HI1214-584R 10.4049/jimmunol.0902501 10.3389/fimmu.2017.00443 10.1111/bjh.16288 10.1016/j.jaci.2019.05.037 10.1126/scitranslmed.aal4712 10.1038/nrc3677 10.1146/annurev-immunol-041015-055354 10.1182/blood.V86.7.2488.2488 10.1073/pnas.1817325115 10.1016/S0002-9440(10)61111-X 10.1016/j.vetimm.2006.11.009 10.3390/ijms20092145 10.3390/jcm8122030 10.4049/jimmunol.182.1.433 10.1371/journal.pone.0026133 10.1161/ATVBAHA.110.206201 10.1371/journal.pone.0148821 10.1371/journal.pone.0043090 10.1182/blood-2013-04-496448 10.1038/leu.2015.4 10.1038/leu.2015.24
Clinical and Experimental Medicine; Marcella S, Petraroli A et. al.

Mar 9th, 2021 - Mastocytosis is a disorder characterized by the abnormal proliferation and/or accumulation of mast cells in different organs. More than 90% of patients with systemic mastocytosis have a gain-of-function mutation in codon 816 of the KIT receptor on...

Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-de...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909134
Medicine Li Y, Jing Y et. al.

Mar 5th, 2021 - Myeloid neoplasms with platelet-derived growth factor receptor β (PDGFRB) rearrangement usually present with eosinophilia in the peripheral blood and bone marrow. Here we report a case of systemic mastocytosis related myeloid neoplasms with basoph...

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level.
https://doi.org/10.1080/21645515.2020.1846398
Human Vaccines & Immunotherapeutics; Selcuk A, Baysan A

Mar 2nd, 2021 - Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episod...

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Co...
https://doi.org/10.1016/j.jid.2020.12.030
The Journal of Investigative Dermatology; Aberer E, Sperr WR et. al.

Feb 13th, 2021 - Mastocytosis is a rare neoplasm characterized by expansion and accumulation of mast cells in various organ systems. Systemic mastocytosis (SM) may or may not presents with cutaneous lesions. To examine the frequency and clinical impact of cutaneou...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  251 results see all →

Clinicaltrials.gov  1,373 results

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993095
Blood Advances; Lim KH, Wu JN et. al.

Mar 18th, 2021 - Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.|2021|Lim KH,Wu JN,Huang TY,Jhuang JY,Chang YC,|

Vascular endothelial growth factors and angiopoietins as new players in mastocytosis.
https://doi.org/10.1007/s10238-021-00693-0 10.3390/ijms20122976 10.1182/blood.2019000932 10.1182/asheducation-2018.1.127 10.1007/s12016-017-8619-2 10.1016/j.iac.2016.08.017 10.1158/0008-5472.CAN-16-2234 10.1016/j.jaci.2017.06.007 10.1159/000500088 10.3389/fncel.2019.00299 10.3390/ijms20102380 10.3390/ijms20143400 10.1016/j.it.2020.06.006 10.3390/ijms20174241 10.3390/ijms20122851 10.1016/j.coph.2014.07.002 10.3390/ijms20184397 10.1136/annrheumdis-2018-213418 10.3390/ijms20081828 10.3390/ijms20092106 10.3390/ijms20184413 10.1111/imr.12634 10.3389/fimmu.2014.00569 10.3389/fimmu.2018.02601 10.1159/000353316 10.1016/j.jaci.2009.01.044 10.1016/j.ejphar.2015.03.088 10.1084/jem.188.6.1135 10.4049/jimmunol.172.2.1227 10.1091/mbc.9.4.875 10.1073/pnas.1000803107 10.1172/JCI70212 10.1038/nrc.2017.51 10.1172/JCI71603 10.3390/vaccines8020208 10.1126/science.6823562 10.1200/JCO.2002.10.088 10.1016/j.cell.2017.10.009 10.1016/S0092-8674(00)81812-7 10.1016/j.cytogfr.2013.05.009 10.1073/pnas.1018925108 10.1152/ajpheart.00621.2002 10.1172/JCI99659 10.1371/journal.pone.0192395 10.1182/blood-2011-08-375816 10.1016/j.intimp.2019.106079 10.1111/all.12862 10.1097/01.shk.0000150728.91155.41 10.1097/MD.0000000000000878 10.1016/j.cyto.2015.01.022 10.1182/blood-2016-09-731893 10.1073/pnas.92.23.10560 10.1182/blood-2013-10-534685 10.1067/mai.2002.120524 10.1124/jpet.105.086553 10.1126/science.277.5322.55 10.1038/nrd.2016.278 10.1182/blood-2009-02-205237 10.1159/000501079 10.1111/j.1398-9995.2010.02372.x 10.18632/oncotarget.4213 10.1016/j.it.2006.10.004 10.3390/cells8050471 10.1016/S0092-8674(00)81813-9 10.1158/0008-5472.CAN-10-4635 10.1096/fj.11-182287 10.1042/CS20160129 10.1038/nature09513 10.1182/blood-2008-12-195941 10.1172/JCI46322 10.1038/74725 10.1182/blood-2003-10-3685 10.1038/nm1351 10.1371/journal.pone.0089148 10.1007/s11882-009-0010-9 10.1203/00006450-200212000-00016 10.1038/nri3690 10.1016/j.jaci.2004.02.032 10.1172/JCI118337 10.1056/NEJM198706253162603 10.1111/j.1365-2362.2009.02184.x 10.1189/jlb.3HI1214-584R 10.4049/jimmunol.0902501 10.3389/fimmu.2017.00443 10.1111/bjh.16288 10.1016/j.jaci.2019.05.037 10.1126/scitranslmed.aal4712 10.1038/nrc3677 10.1146/annurev-immunol-041015-055354 10.1182/blood.V86.7.2488.2488 10.1073/pnas.1817325115 10.1016/S0002-9440(10)61111-X 10.1016/j.vetimm.2006.11.009 10.3390/ijms20092145 10.3390/jcm8122030 10.4049/jimmunol.182.1.433 10.1371/journal.pone.0026133 10.1161/ATVBAHA.110.206201 10.1371/journal.pone.0148821 10.1371/journal.pone.0043090 10.1182/blood-2013-04-496448 10.1038/leu.2015.4 10.1038/leu.2015.24
Clinical and Experimental Medicine; Marcella S, Petraroli A et. al.

Mar 9th, 2021 - Mastocytosis is a disorder characterized by the abnormal proliferation and/or accumulation of mast cells in different organs. More than 90% of patients with systemic mastocytosis have a gain-of-function mutation in codon 816 of the KIT receptor on...

Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-de...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909134
Medicine Li Y, Jing Y et. al.

Mar 5th, 2021 - Myeloid neoplasms with platelet-derived growth factor receptor β (PDGFRB) rearrangement usually present with eosinophilia in the peripheral blood and bone marrow. Here we report a case of systemic mastocytosis related myeloid neoplasms with basoph...

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level.
https://doi.org/10.1080/21645515.2020.1846398
Human Vaccines & Immunotherapeutics; Selcuk A, Baysan A

Mar 2nd, 2021 - Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episod...

Ranitidine - ranitidine tablet, film coated-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0e44d3-615c-4ac6-8e03-eb19ec42e6d4

Feb 22nd, 2021 - Ranitidine tablets USP are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more t...

see more →

News  31 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →